Vor Financial Statements From 2010 to 2026

VOR Stock  USD 13.08  0.55  4.39%   
Vor Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vor Biopharma's valuation are provided below:
Vor Biopharma does not presently have any fundamental trend indicators for analysis.
Check Vor Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vor Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Vor financial statements analysis is a perfect complement when working with Vor Biopharma Valuation or Volatility modules.
Check out the analysis of Vor Biopharma Correlation against competitors.
To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

Vor Biopharma Company Return On Equity Analysis

Vor Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Vor Biopharma Return On Equity

    
  -1.25  
Most of Vor Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vor Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Vor Biopharma has a Return On Equity of -1.2543. This is 94.77% lower than that of the Biotechnology sector and 96.56% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Vor Biopharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Vor Biopharma's current stock value. Our valuation model uses many indicators to compare Vor Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vor Biopharma competition to find correlations between indicators driving Vor Biopharma's intrinsic value. More Info.
Vor Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Vor Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Vor Biopharma Financial Statements

Vor Biopharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Vor Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Vor Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vor Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Vor Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 135 people.

Pair Trading with Vor Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Vor Stock

  0.63CHHE China Health IndustriesPairCorr

Moving against Vor Stock

  0.84IRNRF Iron Road LimitedPairCorr
  0.79DD Dupont De NemoursPairCorr
  0.77CSCO Cisco SystemsPairCorr
  0.75KO Coca ColaPairCorr
  0.72XOM Exxon Mobil CorpPairCorr
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.